MD 📈 Mednax - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061
MD: Newborn Care, Maternal-Fetal Care, Pediatric Cardiology, Subspecialty Care
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida. Web URL: https://www.pediatrix.com
Additional Sources for MD Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MD Stock Overview
Market Cap in USD | 1,241m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1995-09-19 |
MD Stock Ratings
Growth 5y | -45.2% |
Fundamental | -34.6% |
Dividend | - |
Rel. Strength Industry | 1013 |
Analysts | 3.57/5 |
Fair Price Momentum | 14.06 USD |
Fair Price DCF | 37.38 USD |
MD Dividends
No Dividends PaidMD Growth Ratios
Growth Correlation 3m | 68.5% |
Growth Correlation 12m | 57.1% |
Growth Correlation 5y | -66.4% |
CAGR 5y | -12.85% |
CAGR/Mean DD 5y | -0.29 |
Sharpe Ratio 12m | 0.94 |
Alpha | 13.01 |
Beta | 1.40 |
Volatility | 40.70% |
Current Volume | 5048.4k |
Average Volume 20d | 921.3k |
What is the price of MD stocks?
As of December 21, 2024, the stock is trading at USD 14.09 with a total of 5,048,381 shares traded.
Over the past week, the price has changed by +0.14%, over one month by -2.76%, over three months by +33.43% and over the past year by +57.25%.
As of December 21, 2024, the stock is trading at USD 14.09 with a total of 5,048,381 shares traded.
Over the past week, the price has changed by +0.14%, over one month by -2.76%, over three months by +33.43% and over the past year by +57.25%.
Is Mednax a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Mednax (NYSE:MD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.63 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MD as of December 2024 is 14.06. This means that MD is currently overvalued and has a potential downside of -0.21%.
Probably not. Based on ValueRay Fundamental Analyses, Mednax (NYSE:MD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -34.63 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MD as of December 2024 is 14.06. This means that MD is currently overvalued and has a potential downside of -0.21%.
Is MD a buy, sell or hold?
Mednax has received a consensus analysts rating of 3.57. Therefor, it is recommend to hold MD.
Mednax has received a consensus analysts rating of 3.57. Therefor, it is recommend to hold MD.
- Strong Buy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecast for MD stock price target?
According to ValueRays Forecast Model, MD Mednax will be worth about 15.5 in December 2025. The stock is currently trading at 14.09. This means that the stock has a potential upside of +9.87%.
According to ValueRays Forecast Model, MD Mednax will be worth about 15.5 in December 2025. The stock is currently trading at 14.09. This means that the stock has a potential upside of +9.87%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 16.2 | 15% |
Analysts Target Price | 14.5 | 2.9% |
ValueRay Target Price | 15.5 | 9.9% |